Your browser doesn't support javascript.
loading
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial.
Malthaner, Richard A; Yu, Edward; Sanatani, Michael; Lewis, Debra; Warner, Andrew; Dar, A Rashid; Yaremko, Brian P; Bierer, Joel; Palma, David A; Fortin, Dalilah; Inculet, Richard I; Fréchette, Eric; Raphael, Jacques; Gaede, Stewart; Kuruvilla, Sara; Younus, Jawaid; Vincent, Mark D; Rodrigues, George B.
Afiliación
  • Malthaner RA; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Yu E; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Sanatani M; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Lewis D; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Warner A; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Dar AR; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Yaremko BP; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Bierer J; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Palma DA; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Fortin D; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Inculet RI; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Fréchette E; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Raphael J; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Gaede S; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Kuruvilla S; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Younus J; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Vincent MD; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Rodrigues GB; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Thorac Cancer ; 13(13): 1898-1915, 2022 07.
Article en En | MEDLINE | ID: mdl-35611396
ABSTRACT

BACKGROUND:

We compared the health-related quality of life (HRQOL) in patients undergoing trimodality therapy for resectable stage I-III esophageal cancer.

METHODS:

A total of 96 patients were randomized to standard neoadjuvant cisplatin and 5-fluorouracil chemotherapy plus radiotherapy (neoadjuvant) followed by surgical resection or adjuvant cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy (adjuvant) following surgical resection.

RESULTS:

There was no significant difference in the functional assessment of cancer therapy-esophageal (FACT-E) total scores between arms at 1 year (p = 0.759) with 36% versus 41% (neoadjuvant vs. adjuvant), respectively, showing an increase of ≥15 points compared to pre-treatment (p = 0.638). The HRQOL was significantly inferior at 2 months in the neoadjuvant arm for FACT-E, European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-OG25), and EuroQol 5-D-3 L in the dysphagia, reflux, pain, taste, and coughing domains (p < 0.05). Half of patients were able to complete the prescribed neoadjuvant arm chemotherapy without modification compared to only 14% in the adjuvant arm (p < 0.001). Chemotherapy related adverse events of grade ≥2 occurred significantly more frequently in the neoadjuvant arm (100% vs. 69%, p < 0.001). Surgery related adverse events of grade ≥2 were similar in both arms (72% vs. 86%, p = 0.107). There were no 30-day mortalities and 2% vs. 10% 90-day mortalities (p = 0.204). There were no significant differences in either overall survival (OS) (5-year 35% vs. 32%, p = 0.409) or disease-free survival (DFS) (5-year 31% vs. 30%, p = 0.710).

CONCLUSION:

Trimodality therapy is challenging for patients with resectable esophageal cancer regardless of whether it is given before or after surgery. Newer and less toxic protocols are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_digestive_diseases / 6_esophagus_cancer Asunto principal: Neoplasias Esofágicas / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Guideline Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Thorac Cancer Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_digestive_diseases / 6_esophagus_cancer Asunto principal: Neoplasias Esofágicas / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Guideline Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Thorac Cancer Año: 2022 Tipo del documento: Article País de afiliación: Canadá
...